EMERGING OPTIONS IN DEVELOPMENT FOR TREATMENT OF FILOVIRUS INFECTIONS

被引：1
|
作者：
Cardile, A. P. [1 ]
Mayers, D. L. [2 ]
Bavari, S. [3 ]
机构：
[1] US Army Med Res, Inst Infect Dis, Div Med, Frederick, MD 21702 USA
[2] US Army Med Res, Inst Infect Dis, Therapeut Dev Ctr, Frederick, MD 21702 USA
[3] US Army Med Res, Inst Infect Dis, Frederick, MD 21702 USA
来源：
DRUGS OF THE FUTURE | 2015年 / 40卷 / 11期
关键词：
Ebola; Marburg; BCX-4433; Brincidofovir; Favipiravir; Small-interfering RNAs; Antisense phosphorodiamidate; Morpholino oligomers; Interferon; FX-06; zMapp; Recombinant nematode anticoagulant protein c2; Convalescent plasma; Amodiaquine; EBOLA-VIRUS DISEASE; MARBURG VIRUS; NONHUMAN-PRIMATES; RNA INTERFERENCE; CONVALESCENT PLASMA; HEMORRHAGIC-FEVER; FAVIPIRAVIR T-705; POSTEXPOSURE PROTECTION; NUCLEOSIDE ANALOG; YELLOW-FEVER;
D O I：
10.1358/dof.2015.040.11.2387219
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
As a result of the ongoing Ebola outbreak in West Africa, there have been significant developments in therapeutics against Filovirus over the past year. Not only have novel therapeutics been advanced, but a number of already-approved drugs have demonstrated activity against Ebola virus. This review article summarizes the most important therapeutic agents for both Ebola and Marburg virus. Among the therapeutics discussed, small-molecule inhibitors, nucleic acid-based therapeutics, immune-therapeutics (zMapp, convalescent plasma) and repurposed drugs are all included.
引用
收藏
页码：727 / 738
页数：12
相关论文
共 50 条
  • [31] Achromobacter Infections and Treatment Options
    Isler, Burcu
    Kidd, Timothy J.
    Stewart, Adam G.
    Harris, Patrick
    Paterson, David L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
  • [32] Treatment of highly pathogenic filovirus infections using advanced antisense technology
    Travis Warren
    Kelly Warfield
    Jay Wells
    Dana Swenson
    Candace Lovejoy
    Patrick Iversen
    Sina Bavari
    Retrovirology, 7
  • [33] Emerging treatment options for skin and soft tissue infections tailoring drug selection to individual patients
    Castaldo, Nadia
    Vena, Antonio
    Limongelli, Alessandro
    Giacobbe, Daniele Roberto
    Bassetti, Matteo
    CURRENT OPINION IN INFECTIOUS DISEASES, 2024, 37 (02) : 80 - 86
  • [34] Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin
    Righi, Elda
    Carnelutti, Alessia
    Vena, Antonio
    Bassetti, Matteo
    INFECTION AND DRUG RESISTANCE, 2018, 11 : 479 - 488
  • [35] AAV Vectored Immunoprophylaxis for Filovirus Infections
    Rghei, Amira D.
    van Lieshout, Laura P.
    Santry, Lisa A.
    Guilleman, Matthew M.
    Thomas, Sylvia P.
    Susta, Leonardo
    Karimi, Khalil
    Bridle, Byram W.
    Wootton, Sarah K.
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2020, 5 (04)
  • [36] Emerging Treatment Options in Severe Asthma
    Leung, Eric
    Mitchell, Patrick D.
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2018, 14 (02) : 64 - 76
  • [37] Emerging pharmacological treatment options for MAFLD
    Rojas, Angela
    Lara-Romero, Carmen
    Munoz-Hernandez, Rocio
    Gato, Sheila
    Ampuero, Javier
    Romero-Gomez, Manuel
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
  • [38] Emerging treatment options for prostate cancer
    Atiq, Mohammad
    Chandran, Elias
    Karzai, Fatima
    Madan, Ravi A.
    Aragon-Ching, Jeanny B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (06) : 625 - 631
  • [39] Emerging Treatment Options for Carcinoid Syndrome
    Kulke, Matthew H.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (09) : 666 - 667
  • [40] Pathologic features of filovirus infections in humans
    Zaki, SR
    Goldsmith, CS
    MARBURG AND EBOLA VIRUSES, 1999, 235 : 97 - 116
12345